JPMorgan Chase & Co. Acquires 119,574 Shares of Vericel Co. (NASDAQ:VCEL)

JPMorgan Chase & Co. boosted its holdings in Vericel Co. (NASDAQ:VCEL - Free Report) by 26.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 571,194 shares of the biotechnology company's stock after buying an additional 119,574 shares during the period. JPMorgan Chase & Co. owned approximately 1.16% of Vericel worth $31,364,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of VCEL. Arcadia Investment Management Corp MI bought a new stake in shares of Vericel during the 4th quarter valued at $48,000. Smartleaf Asset Management LLC increased its holdings in Vericel by 511.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock valued at $70,000 after purchasing an additional 1,058 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock valued at $138,000 after buying an additional 2,240 shares during the period. KBC Group NV boosted its holdings in Vericel by 82.5% during the fourth quarter. KBC Group NV now owns 2,707 shares of the biotechnology company's stock worth $149,000 after buying an additional 1,224 shares during the last quarter. Finally, Xponance Inc. bought a new stake in shares of Vericel in the 4th quarter valued at about $214,000.

Vericel Trading Down 1.6 %

Shares of VCEL stock traded down $0.65 on Friday, hitting $41.25. 601,588 shares of the stock were exchanged, compared to its average volume of 389,631. The business has a 50-day moving average of $49.21 and a 200 day moving average of $51.42. Vericel Co. has a fifty-two week low of $37.76 and a fifty-two week high of $63.00. The firm has a market capitalization of $2.07 billion, a P/E ratio of 687.61 and a beta of 1.61.

Remove Ads

Insider Transactions at Vericel

In other news, insider Jonathan Siegal sold 3,908 shares of the firm's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $61.99, for a total value of $242,256.92. Following the completion of the transaction, the insider now owns 1,206 shares in the company, valued at $74,759.94. This trade represents a 76.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of the company's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the sale, the director now owns 26,595 shares in the company, valued at $1,662,187.50. The trade was a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 58,942 shares of company stock valued at $2,724,548 in the last ninety days. 5.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Vericel in a report on Friday, February 28th. Stephens reissued an "overweight" rating and issued a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. Canaccord Genuity Group raised their price objective on Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Finally, Truist Financial dropped their price target on Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Vericel currently has a consensus rating of "Moderate Buy" and a consensus target price of $60.86.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.